Leerink Partnrs Issues Optimistic Forecast for ARCT Earnings

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) - Investment analysts at Leerink Partnrs increased their FY2024 EPS estimates for shares of Arcturus Therapeutics in a research note issued on Wednesday, January 22nd. Leerink Partnrs analyst L. Nsongo now anticipates that the biotechnology company will post earnings per share of ($2.55) for the year, up from their previous forecast of ($3.00). The consensus estimate for Arcturus Therapeutics' current full-year earnings is ($2.31) per share. Leerink Partnrs also issued estimates for Arcturus Therapeutics' Q4 2024 earnings at ($0.66) EPS, Q1 2025 earnings at ($0.07) EPS, Q2 2025 earnings at ($0.80) EPS and Q4 2025 earnings at ($0.79) EPS.

A number of other equities research analysts also recently weighed in on ARCT. HC Wainwright reaffirmed a "buy" rating and set a $63.00 price objective on shares of Arcturus Therapeutics in a research report on Monday, January 13th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Arcturus Therapeutics in a research report on Monday, December 16th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $66.75.

Arcturus Therapeutics Stock Down 1.7 %

ARCT stock traded down $0.30 during trading on Friday, hitting $17.12. 280,597 shares of the company's stock traded hands, compared to its average volume of 389,253. The stock has a market capitalization of $463.73 million, a price-to-earnings ratio of -7.71 and a beta of 2.63. Arcturus Therapeutics has a 52 week low of $14.30 and a 52 week high of $45.00. The stock has a fifty day moving average price of $17.28 and a two-hundred day moving average price of $19.69.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last released its earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.70) by $0.44. The company had revenue of $41.67 million for the quarter, compared to the consensus estimate of $49.16 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. During the same quarter last year, the business posted ($0.61) EPS.

Institutional Trading of Arcturus Therapeutics

Several hedge funds have recently added to or reduced their stakes in ARCT. nVerses Capital LLC bought a new stake in shares of Arcturus Therapeutics during the third quarter valued at about $42,000. China Universal Asset Management Co. Ltd. raised its position in shares of Arcturus Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company's stock worth $121,000 after buying an additional 2,038 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Arcturus Therapeutics in the second quarter valued at approximately $142,000. Point72 DIFC Ltd acquired a new position in shares of Arcturus Therapeutics during the second quarter valued at approximately $188,000. Finally, SG Americas Securities LLC bought a new stake in Arcturus Therapeutics during the third quarter worth approximately $191,000. Institutional investors own 94.54% of the company's stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.